Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer

Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer

Abstract Background Breast cancer is the global leading cancer burden in women and the hormone receptor-positive (HR+) subtype is a major part of breast cancer. Though cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are highly effective therapy for HR+ subtype, acquired resistance is inevitable...

Full description

Bibliographic Details
Main Authors: Nar Bahadur Katuwal, Min Sil Kang, Mithun Ghosh, Sa Deok Hong, Yeong Gyu Jeong, Seong Min Park, Seul-Gi Kim, Joohyuk Sohn, Tae Hoen Kim, Yong Wha Moon
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
CDK4/6
ASO
PEG10
HR+ breast cancer
Drug resistance
Online Access:https://doi.org/10.1186/s13046-023-02903-x

Internet

https://doi.org/10.1186/s13046-023-02903-x

Similar Items